Press release
Gilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium
About this update from Gilead Sciences, Inc.
[{"type":"text","content":" FOSTER CITY, Calif.--(BUSINESS WIRE)--\nGilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.\n\n\nData featured in eight presentations include an analysis of clinical outcomes by age from the Phase 3 TROPiCS-02 study of Trodelvy in HR+/HER2- mBC, as well as a qualitative analysis of the experiences and perspectives of patients, caregivers and clinicians on clinical meaningfulness in mBC treatment decision-making. The study adds to a needed body of research exploring the importance of patient-centered interpretations of clinical meaningfulness (e.g., survival, quality of life).\n\n\n“Trodelvy is the first approved Trop-2-directed ADC to significantly improve survival in both second-line metastatic TNBC and pre-treated HR+/HER2- metastatic breast cancer,” said Bill Grossman, MD, PhD, Senior Vice President, Therapeutic Area Head, Gilead Oncology. “The data being presented at SABCS add to the breadth of evidence reinforcing Trodelvy's use in these two difficult-to-treat breast cancers. Additionally, the real-world data being presented in metastatic breast cancer provide insights on quality of life and other measures of health to inform both providers and patients in making treatment decisions.”\n\n\nTable of Accepted Abstracts (all times CDT):\n\n\n\n\nAbstract Disposition\n\n\n\n\n\n\nAbstract Title\n\n\n\n\n\n\n\n\nPoster # PO1-05-09\n\n\n\n\nWednesday, Dec. 6\n\n\n\n\n12:00 PM\n\n\n\n\n\n\nASCENT-07: A Phase 3, Randomized, Open-Label Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients with HR+/HER2- Inoperable, Locally Advanced, or Metastatic Breast Cancer Post-Endocrine Therapy\n\n\n\n\n\n\n\n\nPoster # PO1-06-10\n\n\n\n\nWednesday, Dec. 6\n\n\n\n\n12:00 PM\n\n\n\n\n\n\nOverall Survival Results From EVER-132-001, a Phase 2B Single-Arm Study of Sacituzumab Govitecan in Chinese Patients with Metastatic Triple-Negative Breast Cancer\n\n\n\n\n\n\n\n\nPoster # PO1-04-06\n\n\n\n\nWednesday, Dec. 6\n\n\n\n\n12:00 PM\n\n\n\n\n\n\nExposure-response Analyses of Sacituzumab Govitecan Efficacy and Safety in Patients with Metastatic Breast Cancer\n\n...